Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Thuy Ho, Cara Coleman, Palak Shah & Victor Yazbeck. (2023) Advances in Hodgkin’s lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors. Expert Opinion on Pharmacotherapy 24:13, pages 1427-1438.
Read now
Read now
Tanya Siddiqi, Paul Frankel, Jan H. Beumer, Brian F. Kiesel, Susan Christner, Chris Ruel, Joo Y. Song, Robert Chen, Kevin R. Kelly, Sikander Ailawadhi, Paul Kaesberg, Leslie Popplewell, Sandrine Puverel, Richard Piekarz, Stephen J. Forman & Edward M. Newman. (2020) Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia & Lymphoma 61:2, pages 309-317.
Read now
Read now
Jan Walewski, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, Andrzej Hellmann, Andrea Janikova, Agnieszka Warszewska, Anna Mais, Astrid Ammendola, Thomas Herz, Babett Krauss & Stefan W. Henning. (2019) Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Leukemia & Lymphoma 60:3, pages 675-684.
Read now
Read now
Mayur Narkhede, Maryam Sarraf Yazdy & Bruce Cheson. (2018) Determining the sequence of novel therapies in the treatment of relapsed Hodgkin’s lymphoma. Expert Review of Hematology 11:10, pages 773-780.
Read now
Read now
Bei Hu, Anas Younes, Jason R. Westin, Francesco Turturro, Linda Claret, Lei Feng, Nathan Fowler, Sattva Neelapu, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Felipe Samaniego, Luis E. Fayad, Amanda R. Copeland, Loretta J. Nastoupil, Yago Nieto, Michelle A. Fanale & Yasuhiro Oki. (2018) Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leukemia & Lymphoma 59:4, pages 863-870.
Read now
Read now
Sven Borchmann & Bastian von Tresckow. (2017) Novel agents in classical Hodgkin lymphoma. Leukemia & Lymphoma 58:10, pages 2275-2286.
Read now
Read now
Jesse Keller & Kenneth R Carson. (2015) Risk-adapted strategies for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety 14:10, pages 1519-1530.
Read now
Read now
Patrick M Reagan & Jonathan W Friedberg. (2015) Brentuximab vedotin for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma. Expert Opinion on Orphan Drugs 3:5, pages 609-618.
Read now
Read now
Lori A. Leslie & Anas Younes. (2013) Targeting oncogenic and epigenetic survival pathways in lymphoma. Leukemia & Lymphoma 54:11, pages 2365-2376.
Read now
Read now
Amit Khot, Michael Dickinson & H Miles Prince. (2013)
Panobinostat in lymphoid and myeloid malignancies. Expert Opinion on Investigational Drugs 22:9, pages 1211-1223.
Read now
Read now
Articles from other publishers (48)
Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, Peter Lee, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Jasmine Zain, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak & Alex F. Herrera. (2023) Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 142:16, pages 1359-1370.
Crossref
Crossref
Hummaira Sadaf, Maciej Ambroziak, Robert Binkowski, Jakkapong Kluebsoongnoen, Ewa Paszkiewicz-Kozik, Jaroslaw Steciuk, Sergiusz Markowicz, Jan Walewski, Elzbieta Sarnowska, Tomasz Jacek Sarnowski & Ryszard Konopinski. (2023) New molecular targets in Hodgkin and Reed-Sternberg cells. Frontiers in Immunology 14.
Crossref
Crossref
Fauzia Ullah, Danai Dima, Najiullah Omar, Olisaemeka Ogbue & Sairah Ahmed. (2023) Advances in the treatment of Hodgkin lymphoma: Current and future approaches. Frontiers in Oncology 13.
Crossref
Crossref
Maliha Khan, Fredrick Hagemeister, Michael Wang & Sairah Ahmed. (2022) A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Reviews 55, pages 100949.
Crossref
Crossref
Vigneshwari Easwar Kumar, Roshni Nambiar, Cristabelle De Souza, Audrey Nguyen, Jeremy Chien & Kit S. Lam. (2022) Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. Cells 11:9, pages 1403.
Crossref
Crossref
Narendranath Epperla & Mehdi Hamadani. (2021) Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology 2021:1, pages 247-253.
Crossref
Crossref
Eline A. M. Zijtregtop, Iris van der Strate, Auke Beishuizen, Christian M. Zwaan, Marijn A. Scheijde-Vermeulen, Arianne M. Brandsma & Friederike Meyer-Wentrup. (2021) Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma. Cancers 13:4, pages 884.
Crossref
Crossref
Stephen Booth & Graham Collins. (2020) Epigenetic targeting in lymphoma. British Journal of Haematology 192:1, pages 50-61.
Crossref
Crossref
William Paul SkeltonIVIV, Elyce Turba & Lubomir Sokol. (2020) Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol. Clinical Lymphoma Myeloma and Leukemia 20:12, pages e944-e946.
Crossref
Crossref
Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J. Shpall, Luis E. Fayad, Sattva S. Neelapu, Funda Meric-Bernstam, Razelle Kurzrock & Michelle A. Fanale. (2020) Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research 26:21, pages 5579-5587.
Crossref
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Theodoros P. Vassilakopoulos, John V. Asimakopoulos, Kostas Konstantopoulos & Maria K. Angelopoulou. (2020) Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Therapeutic Advances in Hematology 11, pages 204062072090291.
Crossref
Crossref
David A Pride & Alyssa R Summers. (2018) The emergence of specific HDAC inhibitors and their clinical efficacy in the treatment of hematologic malignancies and breast cancer. International Journal of Molecular Biology 3:5.
Crossref
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Crossref
Yushi Qiu, Zhimin Li, John A. Copland, Thomas Mehrling & Han W. Tun. (2018) Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. Oncotarget 9:46, pages 28155-28164.
Crossref
Crossref
Gunjan L. Shah & Craig H. Moskowitz. (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:15, pages 1689-1697.
Crossref
Crossref
Anja Mottok & Christian Steidl. (2018) Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 131:15, pages 1654-1665.
Crossref
Crossref
Polina Shindiapina & Lapo Alinari. (2018) Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility. Therapeutic Advances in Hematology 9:4, pages 89-105.
Crossref
Crossref
Marcus P. Watkins, Michelle A. Fanale & Nancy L. Bartlett. (2018) SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:2, pages 81-90.
Crossref
Crossref
Max I. Schreuder, Michiel van den Brand, Konnie M. Hebeda, Patricia J. T. A. Groenen, J. Han van Krieken & Blanca Scheijen. (2017) Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. Journal of Hematopathology 10:3-4, pages 91-107.
Crossref
Crossref
Teru Hideshima, Ralph Mazitschek, Jun Qi, Naoya Mimura, Jen-Chieh Tseng, Andrew L. Kung, James E. Bradner & Kenneth C. Anderson. (2017) HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget 8:46, pages 80109-80123.
Crossref
Crossref
Yogesh Jethava, Guru Subramanian Guru Murthy & Mehdi Hamadani. (2017) Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. Hematology/Oncology and Stem Cell Therapy 10:2, pages 47-56.
Crossref
Crossref
Robert Chen. 2017. Management of Lymphomas: A Case-Based Approach. Management of Lymphomas: A Case-Based Approach
205
222
.
Poonam Nagpal, Mohamed R. Akl, Nehad M. Ayoub, Tatsunari Tomiyama, Tasheka Cousins, Betty Tai, Nicole Carroll, Themba Nyrenda, Pritish Bhattacharyya, Michael B. Harris, Andre Goy, Andrew Pecora & K. Stephen Suh. (2016) Pediatric Hodgkin lymphoma- biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget 7:41, pages 67551-67573.
Crossref
Crossref
Lapo Alinari & Kristie A. Blum. (2016) How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood 127:3, pages 287-295.
Crossref
Crossref
Antonino Carbone & Anas YounesConnie Lee Batlevi & Anas Younes. 2015. Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2). Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2)
36
55
.
Leila Haery, Ryan C. Thompson & Thomas D. Gilmore. (2015) Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6:5-6, pages 184-213.
Crossref
Crossref
Sarah Frys, Zachary Simons, Qiang Hu, Matthew J. Barth, Juan J. Gu, Cory Mavis, Joseph Skitzki, Liu Song, Myron S. Czuczman & Francisco J. Hernandez-Ilizaliturri. (2015) Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. British Journal of Haematology 169:4, pages 506-519.
Crossref
Crossref
H. Nagai. (2014) Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. Japanese Journal of Clinical Oncology 45:2, pages 137-145.
Crossref
Crossref
Lohith S Bachegowda & Stefan K Barta. (2014) Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncology 10:15, pages 2509-2528.
Crossref
Crossref
Francesca Montanari & Catherine Diefenbach. (2014) Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 9:3, pages 284-293.
Crossref
Crossref
Christian Marinaccio, Beatrice Nico, Eugenio Maiorano, Giorgina Specchia & Domenico Ribatti. (2014) Insights in Hodgkin Lymphoma angiogenesis. Leukemia Research 38:8, pages 857-861.
Crossref
Crossref
Yasuhiro Oki. (2014) Use of panobinostat in patients with classical Hodgkin lymphoma. International Journal of Hematologic Oncology 3:3, pages 203-210.
Crossref
Crossref
M A Kharfan-Dabaja, M Hamadani, H Sibai & B N Savani. (2014) Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplantation 49:5, pages 599-606.
Crossref
Crossref
Mariano Provencio, Antonio Sánchez & Margarita Sánchez-Beato. (2014) New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treatment Reviews 40:3, pages 457-464.
Crossref
Crossref
Marina Pierdominici, Cristiana Barbati, Marta Vomero, Silvia L. Locatelli, Carmelo Carlo‐Stella, Elena Ortona & Walter Malorni. (2013) Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders. The FASEB Journal 28:2, pages 524-535.
Crossref
Crossref
Catherine Diefenbach & Ranjana Advani. (2014) Customized Targeted Therapy in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 105-122.
Crossref
Crossref
Nida Iqbal, Lalit Kumar & Naveed Iqbal. (2014) Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant. ISRN Oncology 2014, pages 1-7.
Crossref
Crossref
Kristina Keller & Manfred Jung. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
227
255
.
Connie Lee Batlevi & Anas Younes. (2013) Novel therapy for Hodgkin lymphoma. Hematology 2013:1, pages 394-399.
Crossref
Crossref
Xia Zhao, Wei Zhang, Li Wang & Wei-Li Zhao. (2013) Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy. Biomarker Research 1:1.
Crossref
Crossref
Lorella Vecchio, Paul Faustin Seke Etet, Maulilio John Kipanyula, Mauro Krampera & Armel Hervé Nwabo Kamdje. (2013) Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: What can be learned from hematologic malignancies?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1836:1, pages 90-104.
Crossref
Crossref
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild & Bernard M Corfe. (2013) Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches. Clinical Investigation 3:6, pages 571-594.
Crossref
Crossref
Catherine Diefenbach & Christian Steidl. (2013) New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clinical Cancer Research 19:11, pages 2797-2803.
Crossref
Crossref
D Dupéré-Richer, M Kinal, V Ménasché, T H Nielsen, S del Rincon, F Pettersson & W H MillerJrJr. (2013) Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death & Disease 4:2, pages e486-e486.
Crossref
Crossref
Amanda Copeland & Anas Younes. (2012) Current treatment strategies in Hodgkin lymphomas. Current Opinion in Oncology 24:5, pages 466-474.
Crossref
Crossref
Carmela Dell'Aversana, Ilaria Lepore & Lucia Altucci. (2012) HDAC modulation and cell death in the clinic. Experimental Cell Research 318:11, pages 1229-1244.
Crossref
Crossref
Ju-Hee Lee, Megan L. Choy & Paul A. Marks. 2012. Histone Deacetylase Inhibitors as Cancer Therapeutics. Histone Deacetylase Inhibitors as Cancer Therapeutics
39
86
.